ACCELERATE DIAGNOSTICS INC (AXDX) Stock Fundamental Analysis
NASDAQ:AXDX - Nasdaq - US00430H2013 - Common Stock - Currency: USD
We assign a fundamental rating of 0 out of 10 to AXDX. AXDX was compared to 187 industry peers in the Health Care Equipment & Supplies industry. AXDX may be in some trouble as it scores bad on both profitability and health. AXDX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year AXDX has reported negative net income.
In the past year AXDX has reported a negative cash flow from operations.
In the past 5 years AXDX always reported negative net income.
In the past 5 years AXDX always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of AXDX (-175.26%) is worse than 92.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -175.26% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-155.95%
ROA(5y)-129.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AXDX has a worse Gross Margin (23.12%) than 77.78% of its industry peers.
In the last couple of years the Gross Margin of AXDX has declined.
AXDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 23.12% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.89%
GM growth 5Y-13.35%
2. Health
2.1 Basic Checks
AXDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
AXDX has more shares outstanding than it did 1 year ago.
AXDX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AXDX has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -39.29, we must say that AXDX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -39.29, AXDX is not doing good in the industry: 93.12% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -39.29 |
ROIC/WACCN/A
WACC0.32%
2.3 Liquidity
AXDX has a Current Ratio of 0.71. This is a bad value and indicates that AXDX is not financially healthy enough and could expect problems in meeting its short term obligations.
AXDX's Current ratio of 0.71 is on the low side compared to the rest of the industry. AXDX is outperformed by 92.59% of its industry peers.
A Quick Ratio of 0.62 indicates that AXDX may have some problems paying its short term obligations.
AXDX has a Quick ratio of 0.62. This is amonst the worse of the industry: AXDX underperforms 91.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.71 | ||
| Quick Ratio | 0.62 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.33% over the past year.
Looking at the last year, AXDX shows a decrease in Revenue. The Revenue has decreased by -2.97% in the last year.
AXDX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.69% yearly.
EPS 1Y (TTM)35.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.09%
Revenue 1Y (TTM)-2.97%
Revenue growth 3Y-0.23%
Revenue growth 5Y4.69%
Sales Q2Q%-6.97%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.29%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.44%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
AXDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AXDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
AXDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.034
-0.05 (-61.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners18.91%
Inst Owner Change-6.06%
Ins Owners4.32%
Ins Owner Change2.25%
Market Cap857.14K
Analysts85.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.21%
Min EPS beat(2)-23.07%
Max EPS beat(2)25.49%
EPS beat(4)2
Avg EPS beat(4)-2.97%
Min EPS beat(4)-23.07%
Max EPS beat(4)25.49%
EPS beat(8)4
Avg EPS beat(8)8.27%
EPS beat(12)8
Avg EPS beat(12)11.25%
EPS beat(16)9
Avg EPS beat(16)7.76%
Revenue beat(2)0
Avg Revenue beat(2)-5.99%
Min Revenue beat(2)-8.57%
Max Revenue beat(2)-3.41%
Revenue beat(4)0
Avg Revenue beat(4)-4.41%
Min Revenue beat(4)-8.57%
Max Revenue beat(4)-2.74%
Revenue beat(8)0
Avg Revenue beat(8)-9.77%
Revenue beat(12)2
Avg Revenue beat(12)-6.25%
Revenue beat(16)2
Avg Revenue beat(16)-9.26%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)1.67%
Revenue NQ rev (3m)1.67%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.07 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.38
EYN/A
EPS(NY)-2.04
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0.46
BVpS-2.22
TBVpS-2.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -175.26% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 23.12% | ||
| FCFM | N/A |
ROA(3y)-155.95%
ROA(5y)-129.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.89%
GM growth 5Y-13.35%
F-Score3
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 14.88% | ||
| Cap/Sales | 4.35% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.71 | ||
| Quick Ratio | 0.62 | ||
| Altman-Z | -39.29 |
F-Score3
WACC0.32%
ROIC/WACCN/A
Cap/Depr(3y)21.67%
Cap/Depr(5y)26.83%
Cap/Sales(3y)5.75%
Cap/Sales(5y)6.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.09%
EPS Next Y14.29%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.97%
Revenue growth 3Y-0.23%
Revenue growth 5Y4.69%
Sales Q2Q%-6.97%
Revenue Next Year3.44%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.53%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.81%
OCF growth 3YN/A
OCF growth 5YN/A